MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest growing drug classes in human healthcare. lt br / gt lt br / gt Together with its partners in the pharmaceutical industry, MorphoSys has built a therapeutic pipeline of drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. lt br / gt lt br / gt Over therapeutic antibody programs based on the company s technologies are currently in development, of which are in clinical trials. The company s most advanced proprietary program is MOR , a first in class antibody against GM CSF for the treatment of rheumatoid arthritis and multiple sclerosis. MOR is part of MorphoSys s collaboration with GlaxoSmithKline. Other proprietary clinical programs include MOR and MOR , both for the treatment of cancer. lt br / gt lt br / gt MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR.
Quote | Morphosys Ag Ord (OTCMKTS:MPSYF)
Last: | $71.38 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $71.38 |
High: | $0 |
Low: | $0 |
Volume: | 45 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Morphosys Ag Ord (OTCMKTS:MPSYF)
2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...
Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 24, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new efficacy and safety data from the Phase 3 MANIFEST-2 trial of pel...
Message Board Posts | Morphosys Ag Ord (OTCMKTS:MPSYF)
Subject | By | Source | When |
---|---|---|---|
Emylers: MPSYF Financials 07/16/2014 03:24:38 MorphoSys AG Period Ending Total Revenue Cost of Reven | Emylers | investorshangout | 07/16/2014 8:24:35 AM |
Stock_Tracker: Latest Morphosys Ag (MPSYF) Headlines Novartis Strengthens in Oncology With Multiple | Stock_Tracker | investorshangout | 03/10/2014 8:40:12 PM |
chartguy89: MPSYF 97.21 Stock Charts $MPSYF 1 Month Chart | chartguy89 | investorshangout | 03/08/2014 9:38:56 PM |
chartguy89: MPSYF Stock Charts Last: -0.70 Friday, February 28, 2014 at 2:05:11 AM $MPSYF 1 | chartguy89 | investorshangout | 02/28/2014 7:05:23 AM |
News, Short Squeeze, Breakout and More Instantly...
Morphosys Ag Ord Company Name:
MPSYF Stock Symbol:
OTCMKTS Market:
Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 24, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new efficacy and safety data from the Phase 3 MANIFEST-2 trial of pel...
Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billion Shareholders benefit from attractive premium of 94% and 142% on the volume-weighted average price during the last month and three months before January 25, 2024, respectively Acce...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 22, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") in connection with the proposed acquisition of MorphoSys by Novart...